Structure-based design of BACE inhibitors

In a recent post the difficulties of developing drug-like and CNS penetrant inhibitors of β-secretase (BACE-1 or ASP-2) were hinted at (a detailed account of the state of the art can be found in this book).  Many of the reported inhibitors contain a central transition-state isostere flanked by fragments resembling the substrate peptide sequence and, as a result, the physicochemical properties of such molecules (i.e. relatively high MW, logP, PSA, and too many H-bond donor/acceptors) tend to result in inhibitors having poor pharmacokinetic properties and a high degree of P-gp mediated efflux from the CNS.  Various groups have sought to address these issues by seeking novel, non-peptidic core templates (see this recent review for examples) either by fragment-based methods or by de novo structure-based design.  A recent publication from Novartis describes an interesting example of the latter approach which is summarised graphically below:The key hydroxyethylamine motif (which mimics the transition-state during substrate hydrolysis and binds to both of the active site aspartic acid residues), found in many reported inhibitors,  was retained but incorporated into a constrained, cyclic core.  This core was then decorated with non-peptidic groups designed to access the S1, S3, and S2′ recognition pockets (the structural preferences of which are well documented and highly conserved).  Whilst the S2 pocket was not targeted, a functional group X was incorporated into the core with a view to making additional interactions with the protein flap that usually binds over the substrate in the active site (this design approach is similar to that previously reported by DuPont with their cyclic urea, HIV protease inhibitors e.g. Mozenavir).  The Novartis group sought to maximise the probability of obtaining CNS penetrant compounds by targeting an appropriate chemical space (MW<450, ClogP<4, PSA<90, H-bond acceptors<5, pKa<7).  All candidate structures meeting these criteria were docked into the active site and ranked prior to synthesis.  The two compounds shown below were two early compounds they prepared.Whereas the pyran oxygen was unable to form close interactions with the flap the analogous sulfone, which was 50-fold more active, was co-crystallised with BACE (PDB 3PI5) and observed to form optimal H-bonds to Thr72 and Gln73 as hoped.  The aromatic substituents were also observed to make close hydrophobic contacts within the S1 and S2′ pockets and the sulfone had the added and desirable effect of lowering the pKa of the amine by just over 1 order of magnitude relative to the pyran.  Initial attempts to optimise the potency of this series further by extending into the S3 pocket as originally intended were largely unsuccessful and the biggest improvements in potency were obtained by optimisation of the P2′ group (with t-butyl substitution being most potent, see 22c below).  However, significant brain exposure was achieved when 22c was dosed i.v. in mice thus validating the design approach that was taken.  The authors promise future disclosures of steps taken to further improve potency and address the low selectivity (vs Cathepsin D) and metabolic stability issues (22c had a half-life of 6 minutes in rat microsomes) associated with these early exemplars from this series.

This entry was posted in Computational Methods, Enzyme Inhibitors, Med Chem Strategy and tagged , , , , , , , , , , , , , , . Bookmark the permalink.

1 Response to Structure-based design of BACE inhibitors

  1. khush says:

    cn u tell me the binding residues of these S1 S2 S3 pocket?

Leave a Reply to khush Cancel reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s